• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文会议>Conference on Drug Design and Discovery Technologies >AN IN SILICO TARGET SPECIFIC DRUG REPURPOSING APPROACH FOR MULTIPLE SCLEROSIS
【24h】

AN IN SILICO TARGET SPECIFIC DRUG REPURPOSING APPROACH FOR MULTIPLE SCLEROSIS

机译：硅靶特异性药物重新调整方法，用于多发性硬化

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Multiple sclerosis(MS)is a multifocal demyelinating disease with progressive neurodegeneration caused by an increased auto immune response to self-antigens.Based on the ability of remyelination,MS is characterized into 4 subtypes:Relapsing Remitting MS(RRMS)(most commonly found ~87%),Primary Progressive MS(PPMS),Secondary Progressive MS(SPMS),and Progressive Relapsing MS(PRMS).1 MS is termed as T cell-mediated autoimmune disorder with a predominant expression of CD8+ cells,(involved(MHC-I)activation),CD4+ T cells and microglia/macrophages.The pathophysiology of MS involves focal demyelination(myelin sheath destruction),oligodendrocyte destruction and astrocyte proliferation.2 Majority of people experience symptoms like muscle spasms,constipation,weakness,urinary problems and alterative sessions of relapses and remissions between the ages of 20 and 40.3 Currently,Disease Modifying Therapies(DMTs)were known to decrease the frequency and severity of relapses,exacerbations and development of new lesions.To date,U.S FDA approved drug for the treatment of PPMS is Ocrelizumab.Nevertheless,many drugs exhibited success in the preclinical phases and successfully reached clinical trials.Examples of such drugs are:(i)Daclizumab,under phase 2 study(NCT00870740);3(ii)Peginterferonbeta-1a,under phase 3(NCT00906399);4(iii)Glatiramer acetate under phase 3 study(NCT00451451);5 and(iv)Cladribine under phase 3 study(NCT00725985).6 Although drugs are available to treat MS,there's always a research gap in the exploration of genetic mechanisms and pathways involved in progression and re-attacks of the disease.In our present study we made an attempt to identify the disease specific targets and drugs that can be repurposed for the identified targets through an in silico approach using gene expression dataset available in Gene Expression Omnibus(GEO)database.This approach could potentially bypass the extensive work involved in initial stages of de novo drug discovery.
机译：多发性硬化症（MS）是一种多灶性脱髓鞘疾病，其具有增加的自我免疫应答对自我抗原的增加引起的渐进式。基于重新髓鞘的能力，MS的特征在于4个亚型：复发剩余MS（RRMS）（最常见的〜 87％），初级渐进式MS（PPMS），二次逐渐升序MS（SPM）和渐进式复发MS（PRMS）.1 MS被称为T细胞介导的自身免疫疾病，其具有CD8 +细胞的主要表达（参与（MHC- i）活化），CD4 + T细胞和微胶质细胞/巨噬细胞。MS的病理生理学涉及局灶性脱髓鞘（髓鞘纹理），少突胶质细胞破坏和星形胶质细胞增殖.2大多数人经历肌肉痉挛，便秘，泌尿情况和改变等症状。已知疾病修饰治疗（DMT）的疾病改性疗法（DMTS）之间的复发和剩余的会话降低了复发，恶化和发展的频率和严重程度在新病变。迄今为止，美国FDA批准用于治疗PPMS的药物是ocrelizumab.neever，许多药物在临床前相中表现出成功，成功达到了临床试验。这种药物的临床试验是：（i）Daclizumab，在第2阶段研究（NCT00870740）; 3（ii）peginterferonbeta-1a，在第3阶段（NCT00906399）; 4（iii）在第3阶段研究（NCT00451451）的乙酸盐酸盐（NCT00451451）; 5和（IV）克拉酮在第3阶段研究（NCT00725985）。6虽然药物可用于治疗MS，遗传机制探索的研究差距涉及进展和再攻击疾病的进展和再攻击。在我们现在的研究中，我们试图识别可以重新培养的疾病特异性目标和药物对于鉴定的靶通过基因表达综合表达（Geo）数据库中可用的基因表达数据集进行了鉴定的靶。本方法可能会绕过De Novo药物发现的初始阶段所涉及的广泛工作。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号